No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial

• Type of Material: Conference Paper
• Authors: Jonathan Z Li, Brigham & Womens Hospital; Paul E Sax, Brigham & Womens Hospital; Vincent Marconi, Emory University; Jesse Fajnzylber, Brigham & Womens Hospital; Baiba Berzins, Northwestern University; Amesika Nyaku, Rutgers State University; Carl J Fichtenbaum, University of Cincinnati; Timothy Wilkin, Weill Cornell Medicine; Constance A Benson, University of California San Diego; Susan L Koletar, Ohio State University; Ramon Lorenzo-Redondo, Northwestern University; Babafemi O Taiwo, Northwestern University
• Language: English
• Date: 2018-10-01
• Publisher: Emory University Libraries
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofz056
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• Conference or Event Name: Infectious Diseases Society of America
• Volume: 21
• Issue: 3
• Start Page: ofz056
• End Page: ofz056
• Grant/Funding Information: V.C.M., C.J.F., C.A.B., T.W., S.L.K., J.C., J.Z.L., and P.E.S. have received grant funding for this study to their institutions through NU from ViiV/GSK.; This work was supported by an investigator-sponsored study grant from ViiV HealthCare to Northwestern University (NU).; V.C.M. has received funding from the Emory CFAR (P30AI050409).
• Keywords: Science & Technology; Immunology; Infectious Diseases; Life Sciences & Biomedicine
• Research Categories: Health Sciences, Public Health; Health Sciences, Immunology

Abstract

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.